SAR 444836
Alternative Names: SAR-444836Latest Information Update: 28 Aug 2024
At a glance
- Originator Sanofi
- Class Gene therapies
- Mechanism of Action Gene transference; Phenylalanine hydroxylase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Phenylketonuria
Most Recent Events
- 28 Aug 2024 Discontinued - Phase-I/II for Phenylketonuria (In adults) in Turkey (IV) (Sanofi Pipeline, August 2024)
- 23 Feb 2024 SAR 444836 receives Orphan Drug status for Phenylketonuria in USA prior to February 2024
- 07 Aug 2023 Phase-I/II clinical trials in Phenylketonuria (In adults) in Turkey (IV) (NCT05972629)